J Korean Soc Menopause.  2012 Dec;18(3):187-192.

The Effect of Levonorgestrel-releasing Intrauterine System (Mirena(R)) on the Mammographic Density and Breast Ultrasonographic Findings in Korean Premenopausal Women

• Cho SB
• Lee JE
• Lee SR

Abstract

OBJECTIVES
The aim of the present study was to investigate the influence of levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena(R)) on the mammographic density, mammographic findings and breast ultrasonographic findings in Korean premenopausal women.
METHODS
We reviewed medical records of 639 premenopausal women, who inserted LNG-IUS in our department from 2000-2011. Among these, 46 women, who underwent regular mammography (MMG) or breast ultrasonography (USG) examination in radiology department before and after insertion of the LNG-IUS after establishment of picture archiving and communication system (PACS) system in our hospital were finally included in this analysis. We compared the findings of MMG and breast USG between pre- and post-insertion of LNG-IUS. We also checked the pathologic results of any breast biopsy performed in these study participants. The Cochran-Armitage trend test was used to investigate the changes pre- and post-insertion of LNG-IUS.
RESULTS
The mean age of participants was 42.3 +/- 4.9 years and the mean interval period for MMG and US follow-up (FU) was 25.5 +/- 10.8 months and 25.2 +/- 11.5 months, respectively. The density of MMG before insertion of LNG-IUS correlated well with the FU MMG density. The findings of MMG and US also correlated well before and after insertion of LNG-IUS. There was no case of breast cancer among women who were supposed to undergo breast biopsy because of abnormal findings in MMG and US.
CONCLUSION
The use of LNG-IUS did not cause any changes in MMG density, findings of MMG, and findings of breast USG in healthy premenopausal Korean women.

Keyword

Intrauterine system; Levonorgestrel; Mammography; Ultrasonography

MeSH Terms

Biopsy
Breast
Breast Neoplasms
Female
Follow-Up Studies
Humans
Levonorgestrel
Mammary Glands, Human
Mammography
Medical Records
Ultrasonography, Mammary
Breast Neoplasms
Levonorgestrel
Mammary Glands, Human

Reference

1. Luukkainen T, Lähteenmäki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med. 1990. 22:85–90.

2. Shapiro S, Rosenberg L, Hoffman M, Truter H, Cooper D, Rao S, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol. 2000. 151:396–403.

3. Strom BL, Berlin JA, Weber AL, Norman SA, Bernstein L, Burkman RT, et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception. 2004. 69:353–360.

4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996. 347:1713–1727.

5. Sivin I. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. Drug Saf. 2003. 26:303–335.

6. Backman T, Rauramo I, Jaakkola K, Inki P, Vaahtera K, Launonen A, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol. 2005. 106:813–817.

7. Curtis KM. Safety of implantable contraceptives for women: data from observational studies. Contraception. 2002. 65:85–96.

8. Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception. 2011. 83:211–217.